Effectiveness of medicines authentication technology to detect counterfeit, recalled and expired medicines: A two-stage quantitative secondary care study

BMJ Open

Volumn 6, Issue 12, 2016, Pages

  Naughton, Bernard ^a,b,c   Roberts, Lindsey ^d   Dopson, Sue ^b   Chapman, Stephen ^a,e   Brindley, David ^b,e,f,g,h,i  

^a KEELE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d Oxford Academic Health Sciences Network   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g UNIVERSITY OF LONDON   (United Kingdom)

^h HARVARD STEM CELL INSTITUTE   (United States)

ⁱ STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COUNTERFEIT DRUG; DRUG;

ARTICLE; DATA BASE; DRUG RECALL; HUMAN; MEDICAL TECHNOLOGY; MEDICINE AUTHENTICATION TECHNOLOGY; OUTCOME ASSESSMENT; QUANTITATIVE ANALYSIS; SECONDARY HEALTH CARE; MEDICATION ERROR; PHARMACEUTICS; PREVENTION AND CONTROL; PROCEDURES; QUALITATIVE RESEARCH; STANDARDS;

COUNTERFEIT DRUGS; DRUG RECALLS; HUMANS; MEDICATION ERRORS; PHARMACEUTICAL PREPARATIONS; QUALITATIVE RESEARCH; SECONDARY CARE; TECHNOLOGY, PHARMACEUTICAL;

EID: 85006035905     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2016-013837     Document Type: Article

References (29)

1. Research C for DE and. Counterfeit Medicine. [cited 2016 Sep 20]. http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/CounterfeitMedicine/
2. European Medicines Agency-Human regulatory-Falsified medicines. [cited 2015 Jul 9]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/special-topics/general/general-content- 000186.jsp
3. PSI-Inc.org. [cited 2016 Jun 9]. http://www.psi-inc.org/incidentTrends. cfm
4. Almuzaini T, Sammons H, Choonara I. Substandard and falsified medicines in the UK: a retrospective review of drug alerts (2001-2011). BMJ Open 2013;3:e002924.
5. Snapshot. [cited 2016 Jun 9]. http://www.fda.gov/Drugs/DrugSafety/ucm291960.htm
6. Research C for DE and. Drug Safety and Availability-Counterfeit Version of Avastin in U.S. Distribution. [cited 2016 Jun 9]. http://www. fda.gov/Drugs/DrugSafety/ucm291960.htm
7. Counterfeit medicines: what pharmacists should know Drug Safety Update-GOV.UK. [cited 2016 Jun 9]. https://www.gov.uk/drug-safety-update/counterfeit-medicines-what-pharmacists-should-know
8. Fälschungen des Krebspräparats Herceptin in der EU-Schweiz nicht betroffen-Swissmedic. [cited 2016 Jun 9]. https://www. swissmedic.ch/aktuell/00673/02064/index.html?la
9. WHO. WHO | Growing threat from counterfeit medicines. [cited 2016 Jun 9]. http://www.who.int/bulletin/volumes/88/4/10-020410/en/
10. Hanif M, Mobarak MR, Ronan A, et al. Fatal renal failure caused by diethylene glycol in paracetamol elixir: the Bangladesh epidemic. BMJ 1995;311:88-91.
11. The Effects of Falsified and Substandard Drugs-Countering the Problem of Falsified and Substandard Drugs-NCBI Bookshelf. [cited 2016 Jun 9]. http://www.ncbi.nlm.nih.gov/books/NBK202526/#ref-000225
12. Renschler JP, Walters KM, Newton PN, et al. Estimated Under-Five Deaths Associated with Poor-Quality Antimalarials in Sub-Saharan Africa. Am J Trop Med Hyg 2015;92(6 Suppl):119-26.
13. Caunic I, Prelipcean G. The Market for Counterfeit Goods and Financing of the Extremist Organizations in Europe in the Last Decade. In: 2nd International Conference on Humanities, Historical and Social Sciences, IPEDR [Internet]. 2011 [cited 2016 Jun 9]. http://www.ipedr.com/vol17/65-CHHSS%202011-H10119.pdf
14. Kovacs S, Hawes SE, Maley SN, et al. Technologies for Detecting Falsified and Substandard Drugs in Low and Middle-Income Countries. PLoS ONE 2014;9:e90601.
15. Directive 2011/62/EU of the European Parliament and of the Council of 8 June 2011 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use, as regards the prevention of the entry into the legal supply chain of falsified medicinal products Text with EEA relevance-dir-2011-62-en.pdf. [cited 2016 Jun 9]. http://ec.europa.eu/health/files/eudralex/vol-1/dir- 2011-62/dir-2011-62-en.pdf
16. COMMISSION DELEGATED REGULATION (EU) 2016/161-of 2 October 2015-supplementing Directive 2001/83/EC of the European Parliament and of the Council by laying down detailed rules for the safety features appearing on the packaging of medicinal products for human use. [cited 2016 Jun 9]. http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:JOL-2016-032-R-0001&from=EN
17. Naughton BD, Smith JA, Brindley DA. Establishing good authentication practice (GAP) in secondary care to protect against falsified medicines and improve patient safety. Eur J Hosp Pharm Sci Pract 2016;23:118-20.
18. Book Excerpt: Fundamentals of EU Regulatory Affairs, Seventh Edition, Chapter 8: European Union Falsified Medicines Directive: Requirements and Implications for Multi-Stakeholder Healthcare Delivery | RAPS. [cited 2016 Jun 9]. http://www.raps.org/Regulatory-Focus/RAPS-Latest/2015/12/18/23808/Book-Excerpt-Fundamentals-of-EU-Regulatory-Affairs-Seventh-Edition-Chapter-8-European-Union-Falsified-Medicines-Directive-Requirements-and-Implications-for-Multi-Stakeholder-Healthcare-Delivery/
19. Upton F. H.R.3204-113th Congress (2013-2014): Drug Quality and Security Act. 2013 [cited 2016 Jun 9]. https://www.congress.gov/bill/113th-congress/house-bill/3204
20. Naughton B, Vadher B, Smith J, et al. EU Falsified Medicines Directive mandatory requirements for secondary care: a concise review. J Generic Med Bus J Generic Med Sect 2016;12:95-101.
21. 1-Justification-TheNewEstimatesCounterfeit.pdf. [cited 2016 Jun 9]. http://www.who.int/medicines/services/counterfeit/impact/TheNewEstimatesCounterfeit.pdf
22. Sample Size Calculator by Raosoft, Inc. [cited 2016 Jun 9]. http://www.raosoft.com/samplesize.html
23. Sample Size Calculator-Confidence Level, Confidence Interval, Sample Size, Population Size, Relevant Population-Creative Research Systems. [cited 2016 Jun 9]. http://www.surveysystem. com/sscalc.htm
24. Z-test for Proportions-Independent Groups. McCallum Layton. [cited 2016 Jun 9]. https://www.mccallum-layton.co.uk/tools/statistic-calculators/z-test-for-proportions-independent-groups-calculator/
25. Nelson RR. QUARTERLY ExECUTIVE. 2007 [cited 2016 Jun 9]; http://www2.comm.virginia.edu/cmit/Research/MISQE%206-07.pdf
26. Hendy J, Fulop N, Reeves BC, et al. Implementing the NHS information technology programme: qualitative study of progress in acute trusts. BMJ 2007;334:1360.
27. Hendy J, Reeves BC, Fulop N. Challenges to implementing The National programme for information technology (NPfIT): a qualitative study. BMJ 2005;331:331-6.
28. Dopson S, Fitzgerald L, Ferlie E. Understanding change and innovation in healthcare settings: reconceptualizing the active role of context. J Change Manag 2008;8:213-31.
29. Carthey J, Walker S, Deelchand V, et al. Breaking the rules: understanding non-compliance with policies and guidelines. BMJ 2011;343:d5283.